Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

26.8%

11 terminated/withdrawn out of 41 trials

Success Rate

73.2%

-13.3% vs industry average

Late-Stage Pipeline

41%

17 trials in Phase 3/4

Results Transparency

40%

12 of 30 completed trials have results

Key Signals

12 with results10 terminated

Enrollment Performance

Analytics

Phase 2

13(37.1%)

Phase 3

10(28.6%)

Phase 4

7(20.0%)

Phase 1

5(14.3%)

35Total

Phase 2(13)

Phase 3(10)

Phase 4(7)

Phase 1(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (41)

Showing 20 of 41 trials

NCT00464074Completed

Evaluation of Natalizumab for thE Relief of MS Associated FatiGue

Role: collaborator

NCT00035945Phase 2Completed

ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections

Role: collaborator

NCT01791725Phase 2Completed

A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia

Role: collaborator

NCT01674010Phase 2Terminated

Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder

Role: collaborator

NCT01735630Phase 2Completed

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Role: collaborator

NCT01766336Phase 2Terminated

A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Role: collaborator

NCT00306592Phase 3Completed

Natalizumab Re-Initiation of Dosing

Role: collaborator

NCT00871780Phase 4Completed

A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients

Role: collaborator

NCT00027300Phase 3Completed

Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis

Role: collaborator

NCT01070823Completed

JC-Virus (JCV) Antibody Program

Role: collaborator

NCT00083759Phase 2Terminated

Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate

Role: collaborator

NCT00078611Phase 3Completed

A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease

Role: collaborator

NCT00032799Phase 3Completed

Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease

Role: collaborator

NCT00280956Phase 4Completed

Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease

Role: collaborator

NCT00055536Phase 2Completed

Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease

Role: collaborator

NCT00801125Phase 4Withdrawn

Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy

Role: collaborator

NCT00032786Phase 3Completed

Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease

Role: collaborator

NCT00831649Phase 2Terminated

A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201

Role: collaborator

NCT00055367Phase 2Completed

Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease

Role: collaborator

NCT00076544Phase 3Completed

Ziconotide Effectiveness and Safety Trial in Patients With Chronic Severe Pain

Role: lead